Polypeptide-PEG-Fc Complex Preparation via Reducing Agent Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing physiologically active polypeptide complexes with immunoglobulin constant regions using non-peptidyl polymer linkers face challenges of low production yield and reagent deformation, which affect the stability and efficacy of protein drugs.
Innovation Solution
A method involving the reaction of a non-peptidyl polymer with two or more aldehyde functional groups with a physiologically active polypeptide or immunoglobulin constant region, using reducing agents at optimal concentrations to enhance the yield and purity of the complex, specifically using sodium cyanoborohydride or borane pyridine complexes to facilitate the conjugation and coupling reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PEGylation is used to increase molecular weight and circulation time, then in vivo duration is improved, but peptide reactivity decreases and production yield is reduced
Solution Approach 1:
The invention changes the chemical parameters of the conjugation reaction by using cyanoborohydride reducing agents at controlled pH levels (pH 6.0-8.0) to enable efficient conjugation of PEG to insulin while maintaining peptide reactivity. This parameter optimization resolves the contradiction by allowing high molecular weight PEG conjugation without sacrificing production yield.
2Stability of the object's composition
If fusion proteins are used to increase serum half-life, then stability is improved, but in vivo half-life increase is not significant and titers are low
Solution Approach 1:
The invention uses PEG as an intermediary molecule to conjugate insulin with immunoglobulin Fc regions, rather than directly fusing the proteins. This PEG-mediated conjugation approach maintains the stability benefits while achieving significant in vivo half-life extension, resolving the contradiction between stability and duration.
3Duration of action of moving object
If peptidyl linkers are used to maximize serum half-life effect, then in vivo duration is improved, but immune responses are evoked
Solution Approach 1:
The invention replaces peptidyl linkers with PEG-based linkers that are less immunogenic. The PEG linker acts as a biocompatible bridge that achieves the desired pharmacokinetic effects without triggering immune responses, resolving the contradiction between duration enhancement and immune safety.
4Duration of action of moving object
If polypeptides are used as linkers to increase serum half-life, then in vivo duration is improved, but misfolding occurs
Solution Approach 1:
The invention uses PEG as a flexible, non-peptidyl intermediary linker that connects insulin to the immunoglobulin Fc region. This PEG linker avoids the misfolding problems associated with polypeptide linkers while maintaining the ability to extend serum half-life, resolving the contradiction between duration enhancement and structural stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high yield and purity of the complex, enabling the development of long-acting formulations with improved drug compliance and reduced immune responses, maintaining plasma half-life and in vivo duration of physiologically active polypeptides like insulin.
Implementation Method 1
reacting a non-peptidyl polymer having two or more aldehydes as functional groups with one of a physiologically active polypeptide or an immunoglobulin constant region in the presence of a reducing agent
Data Source
AI summary
Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.